论文部分内容阅读
[目的]探讨CK34βE12和Cath-D在乳腺癌组织中的表达水平和临床意义。[方法]用免疫组化法对189例乳腺癌组织和66例癌旁组织中CK34βE12和Cath-D的表达水平进行测定。[结果]CK34βE12的表达与乳腺癌患者的肿瘤大小、组织学分级、病理类型、临床分期、腋淋巴结阳性转移等指标均有显著性相关(P<0.05)。Cath-D的表达与患者的月经状态、雌激素表达、组织学分级、病理类型、临床分期、腋淋巴结阳性转移等指标有显著性相关(P<0.05)。CK34βE12和Cath-D在乳腺癌中的表达无相关性。[结论]CK34βE12或Cath-D可以用来判断乳腺癌的恶性程度和预后。
[Objective] To investigate the expression and clinical significance of CK34βE12 and Cath-D in breast cancer. [Method] The expression levels of CK34βE12 and Cath-D in 189 cases of breast cancer and 66 cases of paracancerous tissues were determined by immunohistochemistry. [Results] The expression of CK34βE12 was significantly correlated with tumor size, histological grade, pathological type, clinical stage and axillary lymph node metastasis in breast cancer patients (P <0.05). The expression of Cath-D was significantly correlated with the menstrual status, estrogen expression, histological grade, pathological type, clinical stage and axillary lymph node metastasis (P <0.05). CK34βE12 and Cath-D in breast cancer expression was not related. [Conclusion] CK34βE12 or Cath-D can be used to judge the malignant degree and prognosis of breast cancer.